logo
The 40+ Best Prime Day TV Deals Our Editors Have Found So Far

The 40+ Best Prime Day TV Deals Our Editors Have Found So Far

Forbes11 hours ago
Amazon Prime Day is coming, and this time, it's more like Prime Days — this year's four-day event will bring about big savings on all sorts of items, from household appliances to top tech. Our editors have been researching some of the best early Prime Day TV deals in the lead-up to the event, and so far, have surfaced some notable discounts on models from Samsung, Hisense and Sony.
Prime Day TV deals can save you hundreds on your nexy big screen television. Illustration: Forbes / Photos: Retailers
While this is the first time Amazon's annual event has lasted more than two days, we're expecting a similar pattern this year as with its shorter sales in the past: New deals across a swathe of categories, TVs included, will likely be released each day and sell out or change quickly. To alert our readers to the most up-to-date information, we'll be tracking prices throughout the sales event and keeping this list current. For your part, we recommend that if you see a deal you like on a top-rated TV or otherwise, you jump on it soon. With that said, here are the best Prime Day TV deals we've seen thus far.
Best Prime Day TV Deals, At A Glance Samsung OLED 4K S85D Series TV (65-Inch): Now $1,200, Was $1,698 (37% Off)
Hisense 55-Inch Class U6 Series Mini-LED 4K TV: Now $448, Was $800 (40% Off)
Insignia 55-Inch Class F50 Series LED 4K UHD TV: Now $190, Was $350 (46% Off)
LG OLED 4K C5 Series Smart TV (65-Inch): Now $1,698, Was $2,698 (37% Off)
Sony Bravia X90L LED 4K TV (55-Inch): Now $848, Was $1,200 (29% Off)
TCL S5 LED 4K TV (55-Inch): Now $250, Was $330 (24% Off) Samsung OLED 4K S85D Series TV (65-Inch): Now $1,200, Was $1,898 (37% Off)
Samsung QLED 4K The Frame LS03D TV (55-Inch): Now $998, Was $1,498 (33% Off)
Samsung OLED 4K S90 Series TV (65-Inch): Now $1,337, Was $1,698 (31% Off)
Samsung OLED 4K S90F Smart TV (77-Inch): Now $2,998, Was $3,398 (12% Off)
Samsung OLED 4K S90D Series TV (55-Inch): Now $1,100, Was $1,798 (39% Off) LG UQ7590 UHD Smart TV (86-Inch): Now $797, Was $1,300 (39% Off)
LG OLED 4K C5 Series Smart TV (65-Inch): Now $1,698, Was $2,698 (37% Off)
LG OLED 4K G5 Series Smart TV (65-Inch): Now $2,905, Was $3,397 (14% Off)
LG OLED 4L C5 Series Smart TV (77-Inch): Now $2,798, Was $3,697 (24% Off)
LG UHD 4K UA77 Series Smart TV (86-Inch): Now $897, Was $1097 (18% Off) Sony Bravia 5 Mini LED 4K TV (85-Inch): Now $2,298, Was $2,800 (18% Off)
Sony Bravia 3 Smart TV (85-Inch): Now $1,298, Was $1,600 (19% Off)
Sony Bravia X90L LED 4K TV (55-Inch): Now $848, Was $1,200 (29% Off)
Sony Bravia 7 QLED LCD TV (65-Inch): Now $1,498, Was $2,000 (25% Off)
Sony Bravia 4K Ultra HD (75-Inch): Now $898, Was $1,100 (18% Off)
Sony 4K Ultra HD (85-Inch): Now $998, Was $1,498 (33% Off)
Sony 4K Ultra HD LED Smart Google TV (55-Inch): Now $498, Was $590 (16% Off) TCL QM85 QLED 4K Google TV (85-Inch): Now $1,698, Was $2,700 (37% Off)
TCL S3 1080p LED Fire TV (40-Inch): Now $150, Was $190 (21% Off)
TCL S4 4K LED TV (50-Inch): Now $309, Was $350 (12% Off)
TCL S5 LED 4K TV (55-Inch): Now $250, Was $330 (24% Off)
TCL Q65 QLED 4K Smart Fire TV (65-Inch): Now $360, Was $400 (10% Off)
TCL QM7 QLED 4K Smart-QD Mini LED TV (85-Inch): Now $1,240, Was $2,000 (38% Off) Hisense ULED 4K Class U8 Mini-LED Google Smart TV (85-Inch): Now $2,400, Was $3,498 (31% Off)
Hisense UHD 4K Class U6 Mini-LED Smart Fire TV (55-Inch): Now $478, Was $800 (40% Off)
Hisense QLED 4K S7N CanvasTV (85-Inch): Now $2,298, Was $4,000 (43% Off)
Hisense UHD 4K Class QD7 Mini-LED Smart Fire TV (85-Inch): Now $950, Was $1,300 (27% Off)
Hisense ULED 4K Class U6 Smart Fire TV (65-Inch): Now $360, Was $450 (20% Off)
Hisense QLED 4K Class QD6 Smart Fire TV (75-Inch): Now $548, Was $700 (22% Off)
Hisense QLED QHD Class QD4 Smart Fire TV (40-Inch): Now $170, Was $250 (32% Off)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies
BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies

Yahoo

time34 minutes ago

  • Yahoo

BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies

BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best new stocks to buy now. On June 18, BrightSpring Health Services announced that its specialty pharmacy, called Onco360, has been chosen as the national pharmacy partner for several newly approved therapies. These innovative treatments target advanced cancers and rare genetic disorders. BrightSpring delivers care and clinical solutions to 400,000+ customers, clients, and patients daily across all 50 states. Onco360 will provide access, education, data, and expert support for patients suffering from advanced ovarian and lung cancers, as well as neurofibromatosis type 1. A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room. Onco360 has been selected as a pharmacy partner for the following specific medication therapies: GOMEKLI, which is approved for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas/PN not suitable for complete resection; AVMAPKI FAKZYNJA CO-PACK, which is approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer/LGSOC who have received prior systemic therapy; and IBTROZI, which is approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that operates through 2 segments: Pharmacy Solutions and Provider Services. Onco360 is a national, independent Oncology Pharmacy and clinical support services company. While we acknowledge the potential of BTSG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments
Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments

Yahoo

time34 minutes ago

  • Yahoo

Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments

Waystar Holding Corp. (NASDAQ:WAY) is one of the best new stocks to buy now. On June 23, Waystar announced the findings of a commissioned study conducted by Forrester Consulting. The study is titled 'AI in Healthcare Payments Software: A Strategic Imperative,' and revealed that AI is becoming increasingly critical in revenue cycle management/RCM due to its proven impact and measurable ROI. The research shows acceleration in AI adoption within healthcare. 82% of healthcare leaders now consider AI an integral part of their RCM operations, with 70% identifying it as a top organizational priority. The study also found that AI is delivering improvements in key revenue cycle metrics, such as a 13% to 37% improvement in high-impact areas such as claim accuracy, denial prevention, workforce efficiency, and payment speed. A medical professional with a patient explaining the effects of neurostimulation treatments. Trust in AI is growing, with 60% of decision-makers reporting increased confidence since implementing AI. ~ 70% of healthcare leaders view AI as a high or critical organizational priority, and 60% plan to increase their AI investment. The study is based on responses from 300+ healthcare leaders and highlights a preference for existing RCM software partners when it comes to AI capabilities. Waystar serves ~30,000 clients and represents over 1 million distinct providers, including 16 of the top 20 institutions on the US News Best Hospitals list. Waystar Holding Corp. (NASDAQ:WAY) develops a cloud-based software solution for healthcare payments. While we acknowledge the potential of WAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Solventum Amends Thermo Fisher Deal, Retains Water Filtration Business
Solventum Amends Thermo Fisher Deal, Retains Water Filtration Business

Yahoo

time34 minutes ago

  • Yahoo

Solventum Amends Thermo Fisher Deal, Retains Water Filtration Business

Solventum Corporation (NYSE:SOLV) is one of the best new stocks to buy now. On June 25, Solventum announced an amendment to its transaction agreement with Thermo Fisher Scientific Inc. (NYSE:TMO). The revised agreement now excludes Solventum's drinking water filtration business from the assets being acquired by Thermo Fisher. Consequently, the cash consideration for the acquisition has been adjusted from ~$4.1 billion to $4 billion. The net proceeds from this sale are intended for debt reduction. This amendment is expected to streamline the transaction and accelerate its closure, which is still expected by the end of this year. Under the new terms, Thermo Fisher will be entitled to a payment of up to $75 million from Solventum. Keeping the Water Business is projected to increase Solventum's annual EPS gain by $0.15 to $0.2. A healthcare professional wearing a health communications device discussing patient data with a colleague. The terms of the amended agreement remain largely consistent with the initial agreement, with modifications specifically reflecting the exclusion of the Water Business. These adjustments include changes to non-compete clauses and related provisions, as well as certain reverse services, manufacturing, and supply agreements that will now support the retained Water Business. Solventum Corporation (NYSE:SOLV) is a healthcare company that develops, manufactures, and commercializes a portfolio of solutions to address customer and patient needs internationally. Thermo Fisher Scientific Inc. (NYSE:TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services internationally. While we acknowledge the potential of SOLV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store